SCHEMBL2750071

SCHEMBL2750071

NCCCC(=O)C(CCN)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 3/20 0.48
CYP1A2 P05177 3/20 0.48
LMNA P02545 2/20 0.48
THRB P10828 2/20 0.48
BLM P54132 2/20 0.48
KMT2A Q03164 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
GABRR3 A8MPY1 1/20 0.48
GABRP O00591 1/20 0.48
GABRD O14764 1/20 0.48
HDAC3 O15379 1/20 0.48
GABBR2 O75899 1/20 0.48
GABRA1 P14867 1/20 0.48
TSHR P16473 1/20 0.48
GABRB1 P18505 1/20 0.48
GABRG2 P18507 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRR2 P28476 1/20 0.48
SLC6A1 P30531 1/20 0.48
GABRA5 P31644 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9827812 0.84 CES2 (0.47) KMT2ATSHRHDAC11MEN1ALDH1A1
SCHEMBL29367483 0.83 LMNA (0.52) GABRR1CYP1A2LMNATHRBBLM
SCHEMBL11677375 0.82 CES2 (0.50) KMT2ATSHRHDAC11MEN1ALDH1A1
SCHEMBL30632246 0.82 CES2 (0.50) KMT2ATSHRHDAC11MEN1ALDH1A1
SCHEMBL6267328 0.82 CES2 (0.50) KMT2ATSHRHDAC11MEN1ALDH1A1
SCHEMBL9827996 0.82 CES2 (0.50) KMT2ATSHRHDAC11MEN1ALDH1A1
SCHEMBL27622246 0.82 CES2 (0.50) KMT2ATSHRHDAC11MEN1ALDH1A1
SCHEMBL11677601 0.82 CES2 (0.50) KMT2ATSHRHDAC11MEN1ALDH1A1
SCHEMBL7500371 0.80 GABRR1 (0.46) GABRR1HDAC3HDAC1HDAC2HDAC8
SCHEMBL9829184 0.79 CPB2 (0.41) GSRRNPEPCPB2LTA4HSLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4351630-A1 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS Antag Therapeutics ApS (DK) 2024-04-17 EP claimed
WO-2022258805-A1 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS ANTAG THERAPEUTICS APS (DK) 2022-12-15 WO claimed
EP-4069719-A1 OPTIMIZED GIP PEPTIDE ANALOGUES Antag Therapeutics ApS (DK) 2022-10-12 EP claimed
CN-114761420-A Optimized GIP peptide analogs 安泰博医药 2022-07-15 CN claimed
US-11572564-B2 Microorganisms for producing 1,4-butanediol and methods related thereto GENOMATICA, INC. (US) 2023-02-07 US disclosed
EP-4069719-A1 OPTIMIZED GIP PEPTIDE ANALOGUES Antag Therapeutics ApS (DK) 2022-10-12 EP disclosed
CN-114761420-A Optimized GIP peptide analogs 安泰博医药 2022-07-15 CN disclosed
US-20160264978-A1 MICROORGANISMS FOR PRODUCING 1,4-BUTANEDIOL AND METHODS RELATED THERETO AGAIN BIO APS (DK) 2016-09-15 US disclosed
US-8178327-B2 Microorganisms for the production of 1,4-butanediol GENOMATICA, INC. (US) 2012-05-15 US disclosed